about
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors.A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors.A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study.Pediatric phase I trial design using maximum target inhibition as the primary endpointEffect of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates.Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.Clinical pharmacokinetics of commonly used anticancer drugs.Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.Incorporation of a fluorescent guanosine analog into oligonucleotides and its application to a real time assay for the HIV-1 integrase 3'-processing reactionA pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors.Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.Dexrazoxane as a cardioprotectant in children receiving anthracyclinesA phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumorsA phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumorsCharacteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitroTime to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).Sorafenib and sunitinib.Trabectedin.Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.Pharmacokinetic drug interactions of commonly used anticancer drugs.Synthesis and fluorescence characterization of pteridine adenosine nucleoside analogs for DNA incorporation.The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model.A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.Evaluation and treatment of fever in the non-neutropenic child with cancer.Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.Real-time fluorescence assay for O6-alkylguanine-DNA alkyltransferase.Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors.
P50
Q27852211-09199A6C-C3AA-4ED3-99D2-5B733917A99EQ33339811-7B4D2ED3-B440-40C4-97ED-865A8986E6FEQ33378668-709FBB08-10C4-47A5-833B-08BC093F1710Q33398261-BA14E989-874E-4275-902C-1DCD40FA0298Q33403207-79F9ABBE-BD74-4412-B85C-1C715264B188Q33496977-C5DF6D58-3DCB-43C7-8694-6BFC6D0653F8Q33915053-362EAF47-ABE0-4B59-90ED-471C95192CC5Q33979288-63E9B0DC-4325-4FF1-B0A5-CAB9A75E4D87Q34131012-44EFC98B-6F4C-4257-A7B6-9567447C28AEQ34131794-C5CFAF9B-E6F0-4DD4-90F8-C037269498E5Q34584174-4E934011-4432-4ECB-A193-7EF537B825EDQ34707699-BD02ABFE-56D9-4738-ADD9-802D5B1708E1Q34743481-128ECF42-1F7E-4835-AA66-339104D7AFEAQ34764444-21B99A9C-4ECF-4A60-BE55-AA077C9ADF9FQ34768677-1B62CBF0-DD4F-4A80-BFA9-7929942CE639Q34817156-74825301-56A0-4286-8E18-3D0BFEF785A4Q35117092-0A5700EB-9867-4CEE-8FF4-10647DD6C285Q35583768-D0D2EBFC-4934-4614-8B86-6927DF69D7F5Q36233516-6F637D5C-D1CA-4AA2-8A71-1DA95149E62FQ36455403-0E09D87B-92E6-4C2A-BBBE-AC5353B5B142Q36564275-CE1E41B3-A460-411E-B12F-24F89E93BBDCQ36920272-13536186-5E90-40DE-BE47-D0E6B0DF0B08Q37104791-BA002DF6-0F98-4D30-B90D-EB452BCB3DC8Q37393469-03D0848E-AB65-4078-BAD6-1142C0DC3A80Q37441129-59EF85D9-C6EE-4EB1-86CA-434871F2C0EBQ37450554-8048673D-88F8-4AB5-9229-1D25919559D6Q37569470-D3B80693-9316-469F-A5D2-168B26645D5AQ37580585-7AD3B12C-2403-486A-9ADB-AC0E55B3C0CBQ37699439-B902B7FB-A571-4416-B520-26B0B1610D93Q38164714-83EEFB1C-32DA-41CE-B3AD-6518A036ED43Q38294902-4CC89522-D624-43AE-B8EF-49219946634AQ38473895-16024A8A-13D0-4B5A-B133-33A0A8BC819DQ39555847-F7B2EBF4-30BF-45E9-9D84-5E2DAC9EC6F6Q39845677-A83CAC64-A4B1-4AC6-A63B-14F82AB05F7EQ40472146-488A2CC0-2F63-49BC-98B1-4D2EEDAB729FQ40552920-6D617167-8346-4825-B0D6-2F39D19C768DQ40572834-2BBB698C-0238-4ABE-B1CA-CCE591BDA8DFQ40871378-144648FA-3408-49FF-AB28-52B168CA7FE8Q42440513-3B09A841-7EA3-4460-B188-4A00EA2F7CABQ43203688-D9B2CA3B-16CC-4BE8-8B37-0E452E3DCA00
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Frank Balis
@ast
Frank Balis
@en
Frank Balis
@es
Frank Balis
@nl
Frank Balis
@sl
type
label
Frank Balis
@ast
Frank Balis
@en
Frank Balis
@es
Frank Balis
@nl
Frank Balis
@sl
prefLabel
Frank Balis
@ast
Frank Balis
@en
Frank Balis
@es
Frank Balis
@nl
Frank Balis
@sl
P106
P1153
7005265756
P21
P31
P496
0000-0002-8117-6926